An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial. - Li X; Benegiamo G; Vijayakumar A; Sroda N; Kimura M; Huss RS; Weng S; Murakami E; Kirby BJ; von Alvensleben GVG; Kremoser C; Gane EJ; et al. (Nature medicine, 2026)